Protagenic Therapeutics, Inc.\new (PTIX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US74365N1037
Price
0.45 USD
Market cap
814,593.60 USD
P/E (2026)
0.76
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
52.23 %
Return on assets (ROA)
37.48 %
Protagenic Therapeutics, Inc.\new financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Revenue | 0.00 USD | 0.00 USD |
| Gross profit | -37,715.00 USD | – |
| Operating income | -5.83 m USD | -4.50 m USD |
| EBIT | -3.59 m USD | 1.37 m USD |
| Net income | -5.16 m USD | 1.37 m USD |
| Diluted EPS – continuing operations | -0.67 USD | 0.59 USD |
Full history since 1995, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Protagenic Therapeutics, Inc.\new
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. The company was founded in 2004 and is based in New York, New York.
More stocks
- Eline Entertainment Group, Inc. (EEGI)
- Adagio Medical Holdings, Inc. (ADGM)
- Nexentis Technologies Inc. (NXTS)
- Lunai Bioworks Inc. (LNAI)
- ProtoKinetix, Inc. (PKTX)
- Cybin Inc (HELP.NE)
- CEMTREX INC (CETX)
- Mentor Capital, Inc. (MNTR)
- Karyopharm Therapeutics Inc. (KPTI)
- Catheter Precision, Inc. (VTAK)
- My Size, Inc. (MYSZ)
- Nu-Med Plus, Inc. (NUMD)
Not investment advice. All data without warranty, price as of 16.11.2026. Details in the risk notice.